Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts

Leukemia. 2004 Sep;18(9):1539-40. doi: 10.1038/sj.leu.2403454.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Blast Crisis / drug therapy*
  • Blast Crisis / genetics
  • Cytogenetic Analysis
  • Female
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Imatinib Mesylate
  • In Situ Hybridization, Fluorescence
  • Interferons / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Male
  • Middle Aged
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Treatment Failure

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Interferons
  • Fusion Proteins, bcr-abl